Motley Fool • 10 hours ago
One has tremendous upside potential, the other is heading for stable growth. To choose the better stock, we'll see how well they stack up.
Zacks • 7 days ago
Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.
Zacks • 11 days ago
Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.
Motley Fool • 14 days ago
Despite a lack of news, shares of the DNA sequencing champ are surging today. Could this be the reason?
Benzinga • 18 days ago
Hemispherx BioPharma, Inc (NYSE: HEB ) is a nano-cap biopharmaceutical research and development company that focuses on the treatment of seriously debilitating disorders. Benzinga recently had the chance ...
Morningstar • 20 days ago
We don't see any major shifts in U.S. drug prices over the next several years, but we expect changes to the Affordable Care Act.
Bloomberg Video • 8 days ago
Jan.09 -- Roche Pharma CEO Daniel O'Day discusses drug pricing and medical care policy changes under the Trump administration. He speaks on “Bloomberg Markets.” (Corrects headline to clarify guest’s title.)
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||29.32 - 29.49|
|52 Week Range||25.25 - 33.77|
|PE Ratio (TTM)||22.75|
|Dividend & Yield||1.02 (3.44%)|
|1y Target Est||34.77|